Tryp Therapeutics CEO James Gilligan joins Natalie Stoberman from the Proactive studio to share how the company is developing psychedelic-assisted therapy in treating various disorders such as binge eating and IBS.
Gilligan says Tryp Therapeutics is taking a unique approach with their product, TRP-8803, which is an IV infusion of psilocin which is an active metabolite of psilocybin. Currently, Gilligan says the company is using oral psilocybin in their studies while preparing for the use of TRP-8803. Tryp Therapeutics has recently secured a $2.4 million private placement that Gilligan says will allow the company to continue their research and upcoming clinical trials.